Antidiabetic Drugs
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2010) | Viewed by 70032
Special Issue Editor
Interests: oxygen radicals; antioxidants; heart failure; atherosclerosis; diabetes; flaxseed and its components; hypertension; hypercholesterolemia; acute coronary syndrome; advanced glycation end products; soluble receptor for advanced glycation end products; C-reactive protein; homocysteine; cytokines; phosphoenolpyruvate carboxykinase
Keywords
- insulin
- exenatide
- pramlintide
- sulfonylurea
- meglitinides
- biguanides
- thiazolidinediones
- glucagon-like peptide (GLP) analogs and agonists
- DPP-4 inhibitors
- amylin analogues
- gastric inhibitory peptide (GIP) analogs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
Related Special Issue
- Anti-Obesity Drugs in Pharmaceuticals (3 articles)